Informing Health Policy Creation: Mandi Bishop Interviews Nicole Fisher

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Prior authorization remains a major health care barrier, causing delays and frustrations for insured adults seeking necessary treatments.

Addressing poor medication adherence should be a top priority in health plans to ensure short- and long-term benefits in health outcomes and financial stability.